Entrada Therapeutics (TRDA) Change in Account Payables (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Change in Account Payables of $641000.0 for Q1 2026, up 133.56% year-over-year from $274447.4 in Q1 2025, and up 173.09% quarter-over-quarter from -$877000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Change in Account Payables (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $641000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 133.56% year-over-year to $641000.0; the TTM figure through Mar 2026 stood at $752000.0 (up 384.85% YoY), while the FY2025 annual figure was -$1.8 million, down 281.53% from the prior year.
- Change in Account Payables for Q1 2026 stood at $641000.0, up from -$877000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $4.6 million in Q4 2022, with the low at -$4.4 million in Q2 2023.
- The 5-year median for Change in Account Payables is -$314000.0 (2024), against an average of $136176.5.
- Peak annual rise in Change in Account Payables reached 869.03% in 2022, while the deepest fall reached 3733.75% in 2022.
- Entrada Therapeutics' Change in Account Payables stood at $4.6 million in 2022, then tumbled by 47.62% to $2.4 million in 2023, then gained by 18.29% to $2.8 million in 2024, then tumbled by 130.82% to -$877000.0 in 2025, then surged by 173.09% to $641000.0 in 2026.
- Business Quant data shows TRDA's Change in Account Payables at $641000.0 in Q1 2026, -$877000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 816,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 816,000.00 |
| Jun 30, 2026 | 816,000.00 |
| Mar 31, 2026 | 641,000.00 |
| Mar 31, 2026 | 641,000.00 |
| Dec 31, 2025 | -877,000.00 |
| Dec 31, 2025 | -877,000.00 |
| Sep 30, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | -321,000.00 |
| Jun 30, 2025 | -321,000.00 |
| Mar 31, 2025 | -1.91 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Sep 30, 2024 | -314,000.00 |
| Sep 30, 2024 | -314,000.00 |
| Jun 30, 2024 | -886,000.00 |
| Jun 30, 2024 | -886,000.00 |
| Mar 31, 2024 | -655,000.00 |
| Mar 31, 2024 | -655,000.00 |